Factors related to survival time in dogs with pulmonary hypertension secondary to degenerative mitral valve disease stage C

Jutamas Udomkiattikul, Nopparson Kirdratanasak, Panatsada Siritanawanitchakul, Wasaporn Worapunyaanun and Sirilak Disatian Surachetpong

Department of Veterinary Medicine, Faculty of Veterinary Science, Chulalongkorn University, Pathumwan, Thailand

ABSTRACT
Pulmonary hypertension (PH) is a common complication in dogs with degenerative mitral valve disease (DMVD). The aim of this study was to determine the survival time and to determine factors related to the survival time of dogs with PH secondary to DMVD stage C. A retrospective study was conducted in 37 dogs with PH secondary to DMVD stage C to analyse the median survival time and associated factors such as age, sex, breed, body weight, the presence of syncope, heart rate, systolic blood pressure, manifestation of congestive heart failure (CHF), vertebral heart score (VHS), the presence of left or right heart enlargement, probability of PH and medication. Data were analysed using the Log-Rank test and plotted with the Kaplan-Meier curve. The results showed that the median survival time of dogs with PH secondary to DMVD stage C was 368 days, and factors that shortened the median survival time of dogs with PH secondary to DMVD stage C were mixed breeds, VHS > 11.5, the presence of right heart enlargement, ascites and high probability of PH. Factors associated with an increased hazard of death were mixed breed dogs, dogs with right heart enlargement and ascites. These findings may be useful for the prognosis and management of dogs with PH secondary to DMVD stage C.

1. Introduction
Degenerative mitral valve disease (DMVD), the most common acquired heart disease in small-breed dogs, is caused by degeneration of the heart valves, leading to systolic mitral valve regurgitation (MR). Common adverse outcomes of DMVD include congestive heart failure (CHF) and pulmonary hypertension (PH) [1,2]. In DMVD, PH may be caused by an initial increase in left ventricular filling pressure to the pulmonary capillaries, which can be reversed in the early stage of the disease. However, in the final stage, when the pulmonary vascular remodelling begins, PH becomes irreversible [3].

Based on the American College of Veterinary Internal Medicine (ACVIM) consensus guidelines for the diagnosis and management of DMVD in dogs [2], DMVD is classified into four stages, depending on cardiac morphology and clinical signs, including stage A, B, C and D. The present study focused on dogs with PH secondary to DMVD stage C with clinical signs of heart failure. The diagnosis of dogs with DMVD stage C is based on clinical findings of heart failure including pulmonary oedema assessed by thoracic radiography and echocardiographic assessment of cardiac remodelling [2].

The development of PH may be caused by increased pulmonary venous pressure, increased pulmonary blood flow and increased pulmonary vascular resistance. The presence of PH has been classified depending on the probability of PH, which is categorized as low, intermediate and high, based on the peak velocity of tricuspid regurgitation (TRV) and the number of different anatomic sites of echocardiographic signs of PH, the severity of PH, and the cause of PH. Clinical findings of PH in dogs included syncope, respiratory distress at rest, exercise intolerance and ascites [4]. One study reported that the detection of PH in dogs with DMVD stage B2 and C is associated with poor prognosis [5].

Few studies have reported the survival time of DMVD dogs at various stages [6,7]. A previous study showed an association of cardiac death with heart murmurs, the ratio of left atrial dimension to the aortic annulus dimension (LA:Ao) > 1.7 and the peak velocity of early diastolic transmural flow (MVEL > 1.2) [6]. Another previous study showed that dyspnoea, pulmonary oedema and vertebral heart score (VHS) > 10.5 were associated with a higher possibility of death [7]. The presence of PH in DMVD dogs was associated with a shorter survival time [5].

As mentioned previously, clinical findings and median survival time may worsen in dogs affected by PH secondary to DMVD. However, there is no study reporting the factors related to the median survival time of PH dogs affected secondary to DMVD stage
C in Thailand. This study aimed to determine the median survival time, prognostic indicators and treatment strategies in dogs with PH secondary to DMVD.

2. Materials and methods

2.1. Data of dogs

Electronic medical records from the Small Animal Teaching Hospital, Faculty of Veterinary Science, Chulalongkorn University from August 2015 to June 2021 were collected. Ethical approval was not required for this study because of its retrospective design. The database assessment was approved by the Chulalongkorn University Small Animal Teaching Hospital Board committees.

Data of thirty-seven dogs affected DMVD stage C with PH were recruited to the study. The inclusion criteria were dogs diagnosed with PH secondary to DMVD stage C and died within June 2021. Diagnostic criteria for DMVD stage C consisted of an echocardiographic examination with the presence of LA:Ao ≥ 1.6 and a normalized left ventricular internal diameter in the diastole (LVIDDN) ≥ 1.7. All dogs had to have past or present clinical signs of left-sided heart failure and evidence of pulmonary oedema assessed by thoracic radiography. Diagnostic criteria for the probability of PH consisted of a TRV > 3 m/s² or a pressure gradient between the right ventricle and right atrium > 46 mmHg, and anatomic sites of the echocardiographic signs of PH [4]. Telephone interviews were conducted to confirm the death or alive status of dogs that the status or date of death could not be reported by the end of June 2021. Dogs that were alive after this date or whose death or alive status could not be confirmed were excluded from the study.

2.2. Clinical evaluation

Left-sided heart failure clinical findings were tachypnoea, restlessness, dyspnoea, cough, exercise intolerance, cyanosis and radiographic findings of pulmonary oedema. Pleural effusion and ascites, the most important clinical findings of right-sided heart failure were also documented. Syncope, a common clinical sign of PH, was also noted.

Data of blood pressure measured by using an ultrasonic Doppler device (model 811; Parks Medical Electronics, Beaverton, Oregon, USA) were recorded. The pressure measurement was performed according to the ACVIM Consensus Guidelines [8]. The cuff size of approximately 40% of limb circumferences was used. Blood pressure was measured at left forelimb around carpal joint area in sternal recumbent position. Blood pressure measurement was performed at least 5 times in each dog in a quiet room to reduce stress induced situational hypertension.

Two views thoracic radiographs (right lateral and ventrodorsal views) were obtained and evaluated. Vertebral heart score was measured according to the method described in a previous study [9]. The right heart enlargement was determined by increased sternal contact in the lateral view or an inverted D-shaped cardiac silhouette in the ventrodorsal view (Figure 1).

Echocardiography was performed by an experienced investigator (SS) using an ultrasound machine (M9, Mindray, China) with multifrequency 4–12 MHz phased-array transducers. Echocardiography was performed without sedation. The right parasternal long-axis view was used to determine the characteristics of the mitral and tricuspid valves. Left ventricular internal diameters in systole (LVIDS) and diastole (LVIDD) were measured in the right parasternal four-chamber view with M-mode echocardiography. M-mode echocardiographic values were normalized by using the Cornell’s allometric scaling method [10]. The percentage of fractional shortening (FS%) was calculated by measuring the percentage change in left ventricular dimension to estimate left ventricular function [11]. The LA/Ao was measured in the right parasternal short-axis view in early diastole [2]. The transmitral early diastolic flow (MV E) and tricuspid regurgitant flow velocities were measured in the left apical four-chamber view [11]. The pressure gradient between right ventricle and right atrium or estimated pulmonary arterial pressure (PAP) was calculated from the tricuspid regurgitant flow velocity using the simplified Bernoulli equation (pressure gradient = 4 \times velocity [m/s])². Figure 1 shows echocardiographic findings of a dog with PH secondary to DMVD stage C.

2.3. Parameters for risk factor analysis

The day of echocardiographic diagnosis of PH secondary to DMVD stage C was defined as the first day of a visit. Echocardiographic parameters evaluated in this study included FS%, LA:Ao, MV E velocity and normalized left ventricular internal diameter in systole (LVIDSN) and in diastole (LVIDDN), according to the Cornell allometric scale method [10]. Information about the dogs was recorded, including age, sex, breed, body weight, the presence of syncope, heart rate, systolic blood pressure, the manifestation of left-sided or biventricular heart failure, radiographic and echocardiographic findings, the presence of left or right heart enlargement, probability of PH, cardiac medical treatments, death-alive status and date of death.

2.4. Statistical analysis

Statistical analysis was performed using a commercial statistical programmed (IBM SPSS 22, USA). Descriptive statistical analysis was used to identify
population characteristics. Univariable Cox regression was used for the hazard of death. The Kaplan-Meier survival curve was applied for survival analysis. The log-rank test was used to compare differences between survival curves. \( P < 0.05 \) was considered statistically significant. Survival time was expressed as median and 95% confidence interval (CI). Data from live dogs at the end of the study were censored.

3. Results

A total of 37 dogs with PH secondary to DMVD stage C were included in this study. The median survival time of 37 dogs with PH secondary to DMVD stage C was 368 days; 95% CI 214.5–584 days. Descriptive data of the dogs recruited for the study, as well as echocardiographic results and medications are presented in Table 1. Data were expressed as medians and interquartile range. There were 17/37 males (45.9%), 13 intact and 4 neutered males, and 20/37 females (54.1%), eight intact and 12 neutered females. The breeds of PH secondary to DMVD stage C dogs in this study were divided into 2 groups. 75.7% (28/37) were purebred dogs and 24.3% (9/37) were mixed breeds. 27% (10/37) were poodles and 73% (27/37) were other breeds including mixed breed (24.3%, 9/37), Chihuahua (21.6%, 8/37), Shih tzu (10.8%, 4/37), Pomeranian (5.4%, 2/37), Miniature pinscher (5.4%, 2/37), Thai Ridgeback (2.7%, 1/37) and Yorkshire (2.7%, 1/37). Thirty-two of 37 dogs (86.5%) had

Figure 1. The radiography of a 10-year-old female poodle dog with pulmonary hypertension (PH) secondary to degenerative mitral valve disease (DMVD). A, the right lateral radiograph shows an enlarged cardiac silhouette with left atrial enlargement (arrow) and caudal lung lobe infiltration. B, the ventrodorsal radiograph shows right heart enlargement and pulmonary artery congestion (arrow). The echocardiography of a 10-year-old male mixed breed dog with PH due to DMVD. C, D, the left apical four chamber view echocardiography shows tricuspid regurgitant flow on colour Doppler on two-dimensional (2D) echocardiography and right atrial (RA) and right ventricular enlargement on 2D echocardiography.
Table 1. Descriptive data of dogs with pulmonary hypertension secondary to degenerative mitral valve disease recruited in the study.

| Category                      | Median   | Interquartile range |
|-------------------------------|----------|---------------------|
| Survival time (days)          | 368      | 214.5–584           |
| Age (years)                   | 12       | 10–14               |
| Weight (kg)                   | 4.7      | 4–6.7               |
| Heart rate (bpm)              | 142      | 130.5–175.5         |
| Blood pressure (mmHg)         | 134      | 112–154.5           |
| VHS                           | 11.9     | 11.15–12.73         |
| Echocardiography              |          |                     |
| Fractional shortening (%)     | 50.42    | 41.43–59.59         |
| LA:Ao                         | 1.87     | 1.76–1.98           |
| MV E velocity (cm/s)          | 142.75   | 128.31–149.35       |
| LVIDSN (mm)                   | 0.99     | 0.76–1.03           |
| LVIDDN (mm)                   | 1.87     | 1.72–2.21           |
| Medication (mg/kg/d)          |          |                     |
| Pirombendan                   | 0.6      | 0.47–0.75           |
| Furosemide                    | 3.14     | 2.38–3.55           |
| Spironolactone                | 2.25     | 1.41–3.28           |
| Benazepril                    | 0.39     | 0.35–0.40           |
| Enalapril                     | 0.74     | 0.65–1.06           |
| Rambipril                     | 0.14     | 0.12–0.19           |
| Sildenafil                    | 1.9      | 1–5.17              |

VHS, Vertebral Heart Scale; LA:Ao, the ratio of left atrial dimension to the aortic annulus dimension; MV E velocity, Peak velocity of early diastolic transmitral flow; LVIDSN, normalized left ventricular internal diameter in systole; LVIDDN, normalized left ventricular internal diameter in diastole; ACEI, angiotensin converting enzyme inhibitor; mg/kg/d, milligram per kilogram per day.

Table 2. The percentage of dogs with pulmonary hypertension secondary to degenerative mitral valve disease categorized in comparison to the median survival time.

| Parameter                      | n   | Category  | Number (%) | P value | Median | 95%CI   |
|--------------------------------|-----|-----------|------------|---------|--------|---------|
| Age (years)                    | 37  | >7        | 34 (91.9)  |         | 453    | 301–605 |
|                                |     | ≤7        | 3 (8.1)    | 0.325   | -      | -       |
| Breed                          | 37  | Mixed     | 28 (75.7)  | 0.009*  | 610    | 377–843 |
|                                |     | Pure      | 10 (27.0)  |         | 652    | 429–875 |
|                                |     | Poodle    | 6 (17.6)   |         | 379    | 199–595 |
|                                |     | Others    | 27 (73.0)  | 0.055   | 368    | 261–475 |
|                                | 37  | Male      | 17 (45.9)  | 0.133   | 621    | 219–1023|
|                                |     | Female    | 20 (54.1)  |         | 368    | 137–599 |
| Syncope                        | 37  | Presence  | 32 (86.5)  | 0.322   | 263    | 221–305 |
|                                |     | Absence   | 5 (13.5)   |         | 502    | 242–762 |
| Heart rate (bpm)**             | 34  | >180      | 6 (17.6)   |         | 379    | 199–595 |
|                                |     | <180      | 28 (82.4)  | 0.812   | 610    | 329–891 |
| Blood pressure (mmHg)**        | 29  | >160      | 23 (79.3)  | 0.32    | 453    | 186–720 |
|                                |     | <160      | 10 (34.4)  |         | 368    | 257–479 |
|                                | 31  | >11.5     | 23 (74.2)  |         | 368    | 257–479 |
|                                |     | 10.5–11.5 | 8 (25.8)   | 0.012*  | 1238   | 0       |
| Right heart enlargement        | 37  | Presence  | 28 (75.7)  | <0.0001*| 236    | 84–388  |
|                                |     | Absence   | 9 (24.3)   |         | 621    | 443–799 |
| Ascsites                       | 37  | Presence  | 32 (86.5)  | 0.016*  | 303    | 17–589  |
|                                |     | Absence   | 5 (13.5)   |         | 601    | 369–851 |
| Echocardiography               |     |           |            |         |        |         |
| Fractional shortening (%)      | 37  | >50       | 18 (48.6)  |         | 453    | 214–692 |
|                                |     | <50       | 19 (51.4)  | 0.419   | 610    | 199–1021|
|                                | 31  | >1.9      | 21 (67.7)  |         | 379    | 249–508 |
|                                |     | <1.9      | 10 (32.3)  | 0.436   | 453    | 152–754 |
|                                | 31  | >150      | 14 (45.2)  |         | 453    | 152–754 |
|                                |     | <150      | 17 (54.8)  | 0.769   | 303    | 0       |
| LVIDSN (mm)                    | 37  | >1        | 17 (45.9)  |         | 397    | 132–662 |
|                                |     | ≤1        | 20 (54.1)  | 0.833   | 453    | 185–721 |
| LVIDDN (mm)                    | 37  | >2        | 18 (48.6)  |         | 368    | 335–401 |
|                                |     | ≤2        | 19 (51.4)  | 0.246   | 253    | 122–384 |
| Probability of PH             | 37  | High      | 11 (30.3)  |         | 453    | 298–608 |
|                                |     | Intermediate | 26 (70.3)  | 0.047*  | 610    | 473–747 |
| Medication Sildenafil          | 37  | Without   | 22 (59.5)  | 0.977   | 453    | 298–608 |
|                                |     | With      | 15 (40.5)  |         | 610    | 279–941 |

VHS, Vertebral Heart Scale; LA:Ao, the ratio of left atrial dimension to the aortic annulus dimension; MV E velocity, Peak velocity of early diastolic transmitral flow; LVIDSN, normalized left ventricular internal diameter in systole; LVIDDN, normalized left ventricular internal diameter in diastole; ACEI, angiotensin converting enzyme inhibitor

* P < 0.05 indicates statistically significant

** Parameters that were not completed in total of 37 dogs due to lack of data

Seven dogs had signs of right ventricular failure. Five dogs had ascites, and four dogs had pleural effusion. Three dogs had both ascites and pleural effusion. Twenty-three dogs died during the study period and 14 dogs were alive at the end of the study. The age of onset ranged from 7 to 17 years. The dogs received pimobendan (89.19%, 33/37), benazepril (10.81%; 4/37), enalapril (13.51%; 5/37), ramipril (64.86%, 24/37), furosemide (100%, 37/37), spironolactone (21.62; 8/37) and sildenafil. The median daily dose of each medication is summarized in Table 1. Summary comparisons of median survival time of PH secondary to DMVD stage C dogs in different categories are shown in Table 2. Mixed breed, VHS >11.5, the presence of right heart enlargement and ascites, and a high probability of PH affected survival time of PH secondary to DMVD stage C dogs (Table 2). Other parameters including age, breed (poodle and others), sex, syncope, heart rate, blood pressure, VHS, fractional shortening, LA:Ao, MV E velocity, LVIDSN, LVIDDN, and sildenafil medication did not affect survival time.
The median survival time of PH secondary to DMVD stage C dogs, between purebred and mixed breeds, was significantly different ($p = 0.009$) (Figure 2 (A), Table 2). Dogs with VHS $>11.5$ ($p = 0.012$; Figure 2 (B), Table 2), right heart enlargement ($p < 0.0001$; Figure 2 (C), Table 2) and the presence of ascites ($p = 0.016$; Figure 2 (D), Table 2) had a shorter survival time than those without. In addition,
the survival time of DMVD dogs with intermediate and high probability of PH was significantly different ($p = 0.047$) (Figure 2 (E), Table 2).

The Cox-regression analysis of numerical and categorical data is summarized in Table 3. Mixed-breed dogs and dogs with VHS $>11.5$, the presence of right heart enlargement and the presence of ascites were associated with an increased hazard of death (Table 3).

4. Discussion

The main findings of this study were: 1) the median survival time of dogs with PH secondary to DMVD stage C was 368 days, 2) mixed-breed dogs and dogs with greater VHS, right heart enlargement, ascites and high probability of PH had shorter survival time of dogs affected by PH secondary to DMVD stage C, 3) mixed-breed dogs and dogs with right heart enlargement and ascites had an increased hazard of death.

The results of this study showed that the median survival time in dogs with PH secondary to DMVD stage C was 368 days. The median survival time from this study was longer than that in dogs with advanced heart failure secondary to DMVD, which was 281 days [12], and in dogs with PH secondary to respiratory disease, which was 276 days [13]. A previous study showed that the median survival time of stage C DMVD dogs was 491 days and that PH dogs secondary to DMVD stage B2 and C had a median survival time of 456 days [5]. However, survival times from different studies are not comparable because various factors such as medications and owner care may influence survival time.

The median age of dogs with PH secondary to DMVD stage C in this study was 12 years (range 10–14 years). This result is in consistent with a previous study suggesting that the prevalence of DMVD in small-breed dogs increases significantly with age (mean 10.7 ± 2.7 years) [5]. However, according to the results of this study, age did not affect the survival time of dogs with PH secondary to DMVD stage C.

Previous studies have shown that small-breed dogs, such as Cavalier King Charles Spaniels (CKCS), Poodles, Chihuahuas and Shih Tzus, are predisposed to development of DMVD [2,14]. A previous study reported that CKCS and other purebred dogs were at higher risk for cardiac-related death than mixed-breed dogs [14]; however, the median survival time of purebred dogs in this study was longer than that of mixed-breed dogs. In addition, mixed-breed dogs had a 3.5 times higher hazard of death than purebred dogs.

Dogs with an increased VHS $>11.5$ tended to have a shorter survival time and a 5.6 times increased hazard of death compared with dogs with a VHS $<11.5$. An increase in heart size is associated with an increase in disease severity. This finding is consistent with a previous study reporting that heart enlargement was associated with decreased survival time and increased risk of death in dogs with DMVD [7]. The presence of right heart enlargement was also associated with a shorter survival time and a 10 times higher hazard of death than in dogs without right heart enlargement in the present study. A previous study has also demonstrated the association between right atrial size and decreased right ventricular function in dogs with PH from various causes [15]. Visser et al [15] also mentioned that enlargement of the right heart is common in dogs with PH. When PH is maintained, the right ventricle has to work harder against the increased pulmonary pressure, and over-load of the right ventricle leads to cardiac remodelling and right ventricular dysfunction. Eventually, right-sided heart failure occurs [16,17]. This leads to fluid accumulation in the abdominal, pleural and/or pericardial cavities [17], which can sometimes be controlled with medication [18]. This study showed that dogs with ascites have a shorter survival time and a 3.4 times higher hazard of death than dogs without ascites. These results suggest that ascites may be used as an indicator of prognosis in dogs with PH secondary to DMVD stage C. More than 80% of dogs in this study had signs of syncope, a common clinical sign of dogs with PH [4]. However, presence of syncope did not affect the survival time of dogs with PH secondary to DMVD stage C in the present study.

The medical treatment of PH secondary to DMVD aims to lower the systolic pulmonary artery pressure (sPAP). Previous studies showed that median survival time of dogs treated with sildenafil was 91 days [19] and 8 to more than 734 days [20]. Medications include platelet-derived growth factor inhibitors, prostacyclin analogues, endothelin antagonists, and phosphodiesterase-5 inhibitors (PDE-5is) [16,20]. Sildenafil is a PDE-5is that has a selective vasodilatory effect on pulmonary vessels [16]. Previous studies have shown that sildenafil can decrease sPAP in PH due to respiratory and cardiovascular diseases [16,20,21]. According to the results of this study, the median survival time of dogs treated with sildenafil was 453 days and without sildenafil was 610 days. Therefore, sildenafil had no effect on the survival time of dogs with PH secondary to DMVD in this study.

Although the study was carefully prepared, data from some dogs were not collected because of the limited information that could be obtained from their owners. This limitation resulted from the retrospective design of the study. Because the missing data were different for each parameter, multivariate regression analysis could not be performed. In addition, data of complete blood counts and blood chemistry could not be analysed in this study because the variation of blood collection time in each dog.
**Table 3.** The result of the Cox-regression analysis in numerical data and categorical data for the hazard of death.

| Parameter | Category | Hazard ratio | 95% CI | P value |
|-----------|----------|--------------|--------|---------|
| Age (years) | 1.146 | 0.970–1.353 | 0.110 |
| Heart rate (bpm) | 1.006 | 0.990–1.022 | 0.460 |
| Blood pressure (mmHg) | 1.001 | 0.983–1.020 | 0.876 |
| VHS | 1.664 | 1.084–2.535 | 0.020* |
| Echocardiography | Fractional shortening (%) | 1.015 | 0.966–1.066 | 0.564 |
| LA:Ao | 2.099 | 0.882–4.995 | 0.094 |
| MV E velocity (cm/s) | 0.999 | 0.985–1.013 | 0.874 |
| LVIDSN (mm) | 0.815 | 0.163–4.075 | 0.803 |
| LVIDDN (mm) | 1.477 | 0.349–6.235 | 0.596 |
| Categorical data |  |  |  |  |
| Age (years) | >7 and ≤7 | 2.644 | 0.353–19.785 | 0.344 |
| Breed | Mixed and Pure | 3.453 | 1.298–9.181 | 0.013* |
| Sex | Male and Female | 0.517 | 0.215–1.241 | 0.140 |
| Syncope | Presence and absence | 1.859 | 0.534–6.471 | 0.330 |
| Heart rate (bpm) | >180 and ≤180 | 1.166 | 0.328–4.150 | 0.812 |
| Blood pressure (mmHg) | >160 and ≤160 | 1.686 | 0.596–4.769 | 0.325 |
| VHS | >11.5 | 5.599 | 0.278–24.522 | 0.022* |
| Right side enlargement | Presence and absence | 10 | 3.193–31.506 | <0.0001* |
| Ascces | Presence and absence | 3.397 | 1.185–9.733 | 0.023* |
| Echocardiography | Fractional shortening (%) | >50 and ≤50 | 1.412 | 0.609–3.277 | 0.421 |
| LA:Ao | >1.9 and ≤1.9 | 1.647 | 0.463–5.864 | 0.441 |
| MV E velocity (cm/s) | >150 and ≤150 | 0.869 | 0.341–2.216 | 0.769 |
| LVIDSN (mm) | >1 and ≤1 | 0.913 | 0.393–2.122 | 0.833 |
| LVIDDN (mm) | >2 and ≤2 | 1.708 | 0.684–4.266 | 0.251 |
| Probability of PH | high and Intermediate | 2.333 | 0.987–5.513 | 0.053 |
| Medication | Sildenafil | 0.988 | 0.423–2.305 | 0.977 |

VHS, Vertebral Heart Scale; LA:Ao, the ratio of left atrial dimension to the aortic annulus dimension; MV E velocity, Peak velocity of early diastolic transmural flow; LVIDSN, normalized left ventricular internal diameter in systole; LVIDDN, normalized left ventricular internal diameter in diastole; ACEI, angiotensin converting enzyme inhibitor

* P < 0.05 indicates statistically significant

## 5. Conclusion

This study reports an estimated survival time of PH secondary to DMVD stage C dogs in Thailand. Mixed breed, VHS > 11.5, the presence of right heart enlargement, ascites and high probability of PH were related to a shorter survival time in dogs with PH secondary to DMVD stage C. Therefore, these parameters should be included in the diagnostic investigation and prognosis of DMVD dogs with PH.

## Acknowledgements

We would like to express gratitude for the grant from academic affairs, Faculty of Veterinary Science Chulalongkorn University and thank Assistant Professor Dr. Vachira Hunprasit and Dr. Lalida Tantisuwat for statistical analysis assistance. Also, we appreciate the dog owners for giving good cooperation and providing information.

## Disclosure statement

No potential conflict of interest was reported by the author(s).

## Funding

This work was supported by the grant from academic affairs, Faculty of Veterinary Science Chulalongkorn University [-].

---

**ORCID**

Sirilak Disatian Surachetpong  http://orcid.org/0000-0001-5041-7849

## References

[1] Chetboul V, Tissier R. Echocardiographic assessment of canine degenerative mitral valve disease. J Vet Cardiol. 2012;14(1):127–148.

[2] Keene BW, Atkins CE, Bonagura JD, et al. ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs. J Vet Intern Med. 2019;33(3):1127–1140.

[3] Guazzi M, Arena R. Pulmonary hypertension with left-sided heart disease. Nat Rev Cardiol. 2010;7(11):648–659.

[4] Reiner C, Visser LC, Kellihan HB, et al. ACVIM consensus statement guidelines for the diagnosis, classification, treatment, and monitoring of pulmonary hypertension in dogs. J Vet Intern Med. 2020;34(2):549–573.

[5] Borgarelli M, Abbott J, Braz-Ruivo L, et al. Prevalence and prognostic importance of pulmonary hypertension in dogs with myxomatous mitral valve disease. J Vet Intern Med. 2015;29(2):569–574.

[6] Borgarelli M, Crosara S, Lamb K, et al. Survival characteristics and prognostic variables of dogs with preclinical chronic degenerative mitral valve disease attributable to myxomatous degeneration. J Vet Intern Med. 2012;26(1):69–75.
[7] Kim HT, Han SM, Song WJ, et al. Retrospective study of degenerative mitral valve disease in small-breed dogs: survival and prognostic variables. J Vet Sci. 2017;18(3):369–376.

[8] Acierno MJ, Brown S, Coleman AE, et al. ACVIM consensus statement: guidelines for the identification, evaluation and management of systemic hypertension in dogs and cats. J Vet Intern Med. 2018;32(6):1803–1822.

[9] Buchanan JW, Bücheler J. Vertebral scale system to measure canine heart size in radiographs. J Am Vet Med Assoc. 1995;206(2):194–199.

[10] Cornell CC, Kittleson MD, Torre PD, et al. Allometric scaling of M-mode cardiac measurements in normal adult dogs. J Vet Intern Med. 2004;18(3):311–321.

[11] Boon JA. Two-dimensional and M-mode echocardiography for the small animal practitioner. 2nd ed. Philadelphia: Willey Blackwell; 2017. p. 86–103.

[12] Beaumier A, Rush JE, Yang VK, et al. Clinical findings and survival time in dogs with advanced heart failure. J Vet Intern Med. 2018;32(3):944–950.

[13] Jaffey JA, Wiggen K, Leach SB, et al. Pulmonary hypertension secondary to respiratory, disease and/or hypoxia in dogs: clinical features, diagnostic testing and survival. Vet J. 2019;251(105347):1–11.

[14] Mattin MJ, Boswood A, Church DB, et al. Prevalence and risk factors for degenerative mitral valve disease in dogs attending primary-care veterinary practices in England. J Vet Intern Med. 2015;29(3):847–854.

[15] Visser LC, Wood JE, Johnson LR. Survival characteristics and prognostic importance of echocardiographic measurements of right heart size and function in dogs with pulmonary hypertension. J Vet Intern Med. 2015;29(3):369–376.

[16] Kellihan HB, Stephien RL. Pulmonary hypertension in canine degenerative mitral valve disease. J Vet Cardiol. 2012;14(1):149–164.

[17] Guglielmini C. Cardiovascular diseases in aging dogs: diagnostic and therapeutic problems. Vet Res Commun. 2003;27(1):555–560.

[18] Ward J, Ware W, Viall A. Association between atrial fibrillation and right-sided manifestation of congestive heart failure in dogs with degenerative mitral valve disease or dilated cardiomyopathy. J Vet Cardiol. 2018;21:8–27.

[19] Bach JF, Rozanski EA, MacGregor J, et al. Rush retrospective evaluation of sildenafil citrate as a therapy for pulmonary hypertension in dogs. J Vet Intern Med. 2006;20(5):1132–1135.

[20] Brown AJ, Davison E, Sleeper MM. Clinical efficacy of sildenafil in treatment of pulmonary arterial hypertension in dogs. J Vet Intern Med. 2010;24(4):850–854.

[21] Saetang K, Surachetpon SG. Short-term effects of sildenafil in the treatment of dogs with pulmonary hypertension secondary to degenerative mitral valve disease. Vet World. 2020;13(10):2260–2268.